Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish
Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovasc...
Saved in:
| Published in: | Biomedicine & pharmacotherapy Vol. 180; p. 117503 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
France
Elsevier Masson SAS
01-11-2024
Elsevier |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib.
To investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish.
AB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing.
Ponatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae.
Our findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity. |
|---|---|
| AbstractList | Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph
ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib.
To investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish.
AB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing.
Ponatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae.
Our findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity. Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib. To investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish. AB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing. Ponatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae. Our findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity. Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib.BACKGROUNDPonatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib.To investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish.PURPOSETo investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish.AB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing.METHODSAB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing.Ponatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae.RESULTSPonatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae.Our findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity.CONCLUSIONOur findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity. Background: Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) who are resistant to the therapies with other tyrosine kinase inhibitors. However, adverse cardiovascular events caused by Ponatinib are a serious issue that affects patients' survival rates. Thus, it is necessary to search for candidate drugs to reduce the cardiovascular toxicity of Ponatinib. Purpose: To investigate the effects of Aspirin on Ponatinib-induced cardiovascular toxicity in zebrafish. Methods: AB strain of wild type zebrafish (Danio rerio), Tg (cmlc2: GFP) transgenic zebrafish, and Tg (gata1: dsRed) transgenic zebrafish were used as in vivo models to assess survival, blood flow, cardiac morphology, and function. Thrombus formation was detected using O-dianisidine staining. The transcriptome of zebrafish larvae treated with Ponatinib was assessed using RNA sequencing. Results: Ponatinib not only reduced survival rate but also caused cardiovascular toxic events such as pericardial edema, abnormal heart structure, low heart rate, and thrombosis. In addition, whole-body transcriptome analysis showed that Ponatinib up-regulated the expression of cyclooxygenase-1 (COX-1). Compared with other antithrombotic drugs, a COX-1 inhibitor Aspirin more effectively reduced ponatinib-induced cardiovascular toxicity events and improved the survival rate of zebrafish larvae. Conclusion: Our findings suggest that Aspirin exhibits the potential to reduce Ponatinib-induced cardiovascular toxicity. |
| ArticleNumber | 117503 |
| Author | Chong, Cheong-Meng Huang, Chen Wang, Danni Bian, Chao Yu, Ruiqi Ai, Nana Ge, Wei |
| Author_xml | – sequence: 1 givenname: Ruiqi surname: Yu fullname: Yu, Ruiqi organization: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China – sequence: 2 givenname: Nana surname: Ai fullname: Ai, Nana organization: Department of Biomedical Sciences and Centre of Reproduction, Development and Aging (CRDA), Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China – sequence: 3 givenname: Chen surname: Huang fullname: Huang, Chen organization: Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, SAR 999078, China – sequence: 4 givenname: Danni surname: Wang fullname: Wang, Danni organization: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China – sequence: 5 givenname: Chao surname: Bian fullname: Bian, Chao organization: Laboratory of Aquatic Genomics, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen 518060, China – sequence: 6 givenname: Wei surname: Ge fullname: Ge, Wei email: weige@um.edu.mo organization: Department of Biomedical Sciences and Centre of Reproduction, Development and Aging (CRDA), Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China – sequence: 7 givenname: Cheong-Meng surname: Chong fullname: Chong, Cheong-Meng email: cmchong@um.edu.mo organization: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macau 999078, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39357328$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtr3DAQx0VJaDbbfoNSfOzFGz2slX0phNBHIJAcUuhNjKRRV4tXciU7JP309dZJjj0NDP8HM79zchJTREI-MLphlG0v9hsT0rCDDae82TCmJBVvyIp1ktZbStUJWVElRS0E52fkvJQ9pVRuRfuWnIlOSCV4uyI_L8sQcohVRjdZLNVdijCGGEwd4nHjKgvZhfQAxU495GpMj8FWww5jGp-G2QHRVQ5h3FVzzB80GXwou3fk1ENf8P3zXJMfX7_cX32vb26_XV9d3tSWc97W6KhQHQqLrZXAaAOeITC0bWu2DA3zAqVUneBKUHCAwnPpuPWm4eCaRqzJ9ZLrEuz1kMMB8pNOEPS_Rcq_NOQx2B61ksoYyltuKTZN2wHS1kv0DLyS0Jg569OSNeT0e8Iy6kMoFvseIqapaMEYl1yx-dNr0ixSm1MpGf1rNaP6yEfv9cJHH_nohc9s-_jcMJkDulfTC5BZ8HkR4Pyzh4BZFxswzhxCRjvOR4X_N_wFOlalsw |
| Cites_doi | 10.1007/s12012-015-9315-1 10.3390/biomedicines12030693 10.1002/hon.2606 10.1007/s40265-014-0216-6 10.1038/sj.clpt.6100223 10.1038/nrd4627 10.1158/1535-7163.MCT-11-0450 10.1101/cshperspect.a006684 10.3389/fonc.2021.642005 10.1016/j.leukres.2016.07.007 10.1124/jpet.117.246116 10.1056/NEJMoa1609324 10.1038/ng0498-345 10.1016/j.ejphar.2020.173292 10.1111/j.1365-2125.2011.03943.x 10.1016/j.exphem.2013.12.007 10.1371/journal.pone.0285216 10.1371/journal.pgen.1005783 10.3892/or.2013.2386 10.1186/s13578-022-00838-y 10.3390/pharmaceutics16030383 10.1182/bloodadvances.2019000034 10.1159/000504664 10.1016/j.thromres.2014.11.009 10.18632/oncotarget.24110 10.1152/ajpheart.01105.2006 10.1016/j.bbrc.2006.11.007 10.1186/s13578-023-01064-w 10.1016/j.freeradbiomed.2023.08.021 10.1038/s12276-023-01002-3 10.1016/j.drudis.2008.03.002 10.1016/j.chemosphere.2017.04.090 10.1007/5584_2016_123 10.1523/JNEUROSCI.2373-09.2009 10.1097/MOH.0000000000000075 10.1371/journal.pone.0294438 10.1182/bloodadvances.2019000268 10.1016/S1470-2045(16)00080-2 10.1002/dvdy.24497 10.1002/bies.10326 10.1158/1535-7163.MCT-10-1044 10.1093/cvr/cvz006 10.1002/mco2.363 10.1111/j.1365-2141.2012.09085.x 10.1016/j.ccr.2009.09.028 10.1089/zeb.2016.1263 10.1371/journal.pone.0020062 10.3390/cells11060943 10.1634/theoncologist.2015-0253 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| Copyright_xml | – notice: 2024 The Authors – notice: Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| DBID | 6I. AAFTH NPM AAYXX CITATION 7X8 DOA |
| DOI | 10.1016/j.biopha.2024.117503 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1950-6007 |
| ExternalDocumentID | oai_doaj_org_article_757bb0282c0e4489ae08f5ef1af75a4b 10_1016_j_biopha_2024_117503 39357328 S0753332224013891 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 23N 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6I. 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAFTH AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO ABBQC ABFNM ABMAC ABMZM ABXDB ABZDS ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD ADVLN AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFPKN AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA GROUPED_DOAJ HMT HVGLF HZ~ IHE J1W KOM M34 M41 MO0 N9A NCXOZ O-L O9- OAUVE OD~ OGGZJ OK1 OO0 OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SEM SES SEW SPT SSH SSP SSZ T5K VH1 WUQ Z5R ~02 ~G- NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c2228-ed0379e3ce8c5a104af1ea1ec88b61eb1f3e557932730adae3f25d2cfb42ad443 |
| IEDL.DBID | DOA |
| ISSN | 0753-3322 1950-6007 |
| IngestDate | Mon Nov 18 19:22:32 EST 2024 Thu Nov 14 17:20:57 EST 2024 Wed Nov 20 13:25:08 EST 2024 Sat Nov 02 12:22:00 EDT 2024 Sat Nov 16 16:00:19 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Zebrafish Aspirin Ponatinib Cardiovascular toxicity COX-1 Thrombosis |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2228-ed0379e3ce8c5a104af1ea1ec88b61eb1f3e557932730adae3f25d2cfb42ad443 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doaj.org/article/757bb0282c0e4489ae08f5ef1af75a4b |
| PMID | 39357328 |
| PQID | 3112527150 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_757bb0282c0e4489ae08f5ef1af75a4b proquest_miscellaneous_3112527150 crossref_primary_10_1016_j_biopha_2024_117503 pubmed_primary_39357328 elsevier_sciencedirect_doi_10_1016_j_biopha_2024_117503 |
| PublicationCentury | 2000 |
| PublicationDate | 20241101 |
| PublicationDateYYYYMMDD | 2024-11-01 |
| PublicationDate_xml | – month: 11 year: 2024 text: 20241101 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | Biomedicine & pharmacotherapy |
| PublicationTitleAlternate | Biomed Pharmacother |
| PublicationYear | 2024 |
| Publisher | Elsevier Masson SAS Elsevier |
| Publisher_xml | – name: Elsevier Masson SAS – name: Elsevier |
| References | Castagnetti, Pane, Rosti, Saglio, Breccia (bib48) 2021; 11 Caocci, Mulas, Abruzzese, Luciano, Iurlo, Attolico, Castagnetti, Galimberti, Sgherza, Bonifacio, Annunziata, Gozzini, Orlandi, Stagno, Binotto, Pregno, Fozza, Trawinska, De Gregorio, Cattaneo, Albano, Gugliotta, Barate, Scaffidi, Elena, Pirillo, Scalzulli, La Nasa, Foa, Breccia (bib26) 2019; 37 Langheinrich (bib13) 2003; 25 Ishikawa, Griffin, Banerjee, Herschman (bib40) 2007; 352 MacRae, Peterson (bib14) 2015; 14 Zhang, Zhou, Gao, Wang, Fang, Li, Yu, Kong, Xing, Gao (bib45) 2014; 7 Zhu, Xia, Ye, Dai, Yang, Li, Li (bib24) 2020; 889 Garcia-Bueno, Serrats, Sawchenko (bib42) 2009; 29 Gozgit, Wong, Moran, Wardwell, Mohemmad, Narasimhan, Shakespeare, Wang, Clackson, Rivera (bib1) 2012; 11 McGrath, Li (bib15) 2008; 13 Loren, Aslan, Rigg, Nowak, Healy, Gruber, Druker, McCarty (bib7) 2015; 135 Wang, Travers, Farrell, Lu, Bays, Stepanian, Chen, Jaffe (bib34) 2023; 18 Dorer, Knickerbocker, Baccarani, Cortes, Hochhaus, Talpaz, Haluska (bib8) 2016; 48 Chan, Talati, Isenalumhe, Shams, Nodzon, Fradley, Sweet, Pinilla-Ibarz (bib33) 2020; 4 Chen, Liu, Li, Wang, Yuan, Yin, Chen, Hu, Yao, Zhang, Wu, Chen (bib16) 2022; 12 Gainor, Chabner (bib9) 2015; 20 Cui, Chen, Cui, Guo, Fang, Liu, Chen, Lee (bib22) 2016; 16 Shah, Seeley, Schulz, Fisher, Gururaja Rao (bib28) 2022; 11 Merkulova, Mitchell, Stavrou, Forbes, Schmaier (bib32) 2019; 3 Kari, Rodeck, Dicker (bib11) 2007; 82 Born, Patrono (bib37) 2006; 147 Zhang, Liu, Sun, Zhang, Guo, Ma (bib39) 2023; 4 Zirm, Spies-Weisshart, Heidel, Schnetzke, Bohmer, Hochhaus, Fischer, Scholl (bib5) 2012; 157 Kim, Cho, Lim, Seok, Lee (bib50) 2023; 55 Tailor, Wood, Wallace, Specian, Granger (bib38) 2007; 293 Ren, Hong, Liu, Wang, Patel, Biddinger, Silva, Cowell, Hao (bib4) 2013; 29 Zhu, Liu, Guo, Xia, Song, Lao, Xuan, Li (bib21) 2016; 13 De Paolo, Sarti, Bernardi, Cucco, Tavosanis, Pitto, Poliseno (bib17) 2023; 13 O'Hare, Shakespeare, Zhu, Eide, Rivera, Wang, Adrian, Zhou, Huang, Xu, Metcalf, 3rd, Tyner, Loriaux, Corbin, Wardwell, Ning, Keats, Wang, Sundaramoorthi, Thomas, Zhou, Snodgrass, Commodore, Sawyer, Dalgarno, Deininger, Druker, Clackson (bib2) 2009; 16 Zhang, Zhang, Ding (bib36) 2017; 906 Singh, Glennon, Umbarkar, Gupte, Galindo, Zhang, Force, Becker, Lal (bib25) 2019; 115 Hoy (bib10) 2014; 74 Lipton, Chuah, Guerci-Bresler, Rosti, Simpson, Assouline, Etienne, Nicolini, le Coutre, Clark, Stenke, Andorsky, Oehler, Lustgarten, Rivera, Clackson, Haluska, Baccarani, Cortes, Guilhot, Hochhaus, Hughes, Kantarjian, Shah, Talpaz, Deininger, Investigators (bib43) 2016; 17 Sadovnik, Lierman, Peter, Herrmann, Suppan, Stefanzl, Haas, Lion, Pickl, Cools, Vandenberghe, Valent (bib3) 2014; 42 Liu, Chu, Chen, Gui, Zhu (bib23) 2017; 181 Galimberti, Abruzzese, Luci, Barate, Luciano, Iurlo, Caocci, Morganti, Stefanelli, Di Paolo (bib47) 2024; 16 Postlethwait, Yan, Gates, Horne, Amores, Brownlie, Donovan, Egan, Force, Gong, Goutel, Fritz, Kelsh, Knapik, Liao, Paw, Ransom, Singer, Thomson, Abduljabbar, Yelick, Beier, Joly, Larhammar, Rosa, Westerfield, Zon, Johnson, Talbot (bib12) 1998; 18 Hochhaus, Larson, Guilhot, Radich, Branford, Hughes, Baccarani, Deininger, Cervantes, Fujihara, Ortmann, Menssen, Kantarjian, O'Brien, Druker (bib44) 2017; 376 Yalcin, Amindari, Butcher, Althani, Yacoub (bib30) 2017; 246 Laramy, Kim, Parrish, Sarkaria, Elmquist (bib46) 2018; 365 Ai, Wang, Qu, Vong, Yuan, Su, Ge, Chong (bib18) 2023; 208 Fernandez-Murray, Prykhozhij, Dufay, Steele, Gaston, Nasrallah, Coombs, Liwski, Fernandez, Berman, McMaster (bib51) 2016; 12 Ai, Chong, Chen, Hu, Su, Chen, Lei Wong, Ge (bib19) 2018; 9 Angom, Nakka (bib31) 2024; 12 Warner, Nylander, Whatling (bib35) 2011; 72 Wang, Lan, Lu, Li, Liao, Xu, Sun, Tang, Wang, Mei, Wei, Wu, Zhu (bib41) 2023; 18 Gozgit, Wong, Wardwell, Tyner, Loriaux, Mohemmad, Narasimhan, Shakespeare, Wang, Druker, Clackson, Rivera (bib6) 2011; 10 Armstrong, Kirkby, Zain, Emerson, Mitchell, Warner (bib27) 2011; 6 Weyand, Shavit (bib20) 2014; 21 Gore, Monzo, Cha, Pan, Weinstein (bib29) 2012; 2 Santoro, Accurso, Mancuso, Contrino, Sardo, Novo, Di Piazza, Perez, Russo, Siragusa (bib49) 2019; 64 Fernandez-Murray (10.1016/j.biopha.2024.117503_bib51) 2016; 12 Sadovnik (10.1016/j.biopha.2024.117503_bib3) 2014; 42 Langheinrich (10.1016/j.biopha.2024.117503_bib13) 2003; 25 Singh (10.1016/j.biopha.2024.117503_bib25) 2019; 115 Tailor (10.1016/j.biopha.2024.117503_bib38) 2007; 293 Caocci (10.1016/j.biopha.2024.117503_bib26) 2019; 37 O'Hare (10.1016/j.biopha.2024.117503_bib2) 2009; 16 Cui (10.1016/j.biopha.2024.117503_bib22) 2016; 16 MacRae (10.1016/j.biopha.2024.117503_bib14) 2015; 14 Merkulova (10.1016/j.biopha.2024.117503_bib32) 2019; 3 Loren (10.1016/j.biopha.2024.117503_bib7) 2015; 135 Ai (10.1016/j.biopha.2024.117503_bib19) 2018; 9 Ishikawa (10.1016/j.biopha.2024.117503_bib40) 2007; 352 Shah (10.1016/j.biopha.2024.117503_bib28) 2022; 11 Gore (10.1016/j.biopha.2024.117503_bib29) 2012; 2 Chen (10.1016/j.biopha.2024.117503_bib16) 2022; 12 Yalcin (10.1016/j.biopha.2024.117503_bib30) 2017; 246 Zhang (10.1016/j.biopha.2024.117503_bib39) 2023; 4 Liu (10.1016/j.biopha.2024.117503_bib23) 2017; 181 Armstrong (10.1016/j.biopha.2024.117503_bib27) 2011; 6 Zirm (10.1016/j.biopha.2024.117503_bib5) 2012; 157 Hoy (10.1016/j.biopha.2024.117503_bib10) 2014; 74 Lipton (10.1016/j.biopha.2024.117503_bib43) 2016; 17 Gozgit (10.1016/j.biopha.2024.117503_bib6) 2011; 10 Santoro (10.1016/j.biopha.2024.117503_bib49) 2019; 64 Zhang (10.1016/j.biopha.2024.117503_bib45) 2014; 7 Angom (10.1016/j.biopha.2024.117503_bib31) 2024; 12 Gainor (10.1016/j.biopha.2024.117503_bib9) 2015; 20 Ai (10.1016/j.biopha.2024.117503_bib18) 2023; 208 Zhu (10.1016/j.biopha.2024.117503_bib24) 2020; 889 Chan (10.1016/j.biopha.2024.117503_bib33) 2020; 4 Wang (10.1016/j.biopha.2024.117503_bib41) 2023; 18 Kim (10.1016/j.biopha.2024.117503_bib50) 2023; 55 Warner (10.1016/j.biopha.2024.117503_bib35) 2011; 72 Hochhaus (10.1016/j.biopha.2024.117503_bib44) 2017; 376 Garcia-Bueno (10.1016/j.biopha.2024.117503_bib42) 2009; 29 Laramy (10.1016/j.biopha.2024.117503_bib46) 2018; 365 Castagnetti (10.1016/j.biopha.2024.117503_bib48) 2021; 11 Gozgit (10.1016/j.biopha.2024.117503_bib1) 2012; 11 Galimberti (10.1016/j.biopha.2024.117503_bib47) 2024; 16 Weyand (10.1016/j.biopha.2024.117503_bib20) 2014; 21 Born (10.1016/j.biopha.2024.117503_bib37) 2006; 147 Ren (10.1016/j.biopha.2024.117503_bib4) 2013; 29 Kari (10.1016/j.biopha.2024.117503_bib11) 2007; 82 Zhang (10.1016/j.biopha.2024.117503_bib36) 2017; 906 Wang (10.1016/j.biopha.2024.117503_bib34) 2023; 18 Zhu (10.1016/j.biopha.2024.117503_bib21) 2016; 13 De Paolo (10.1016/j.biopha.2024.117503_bib17) 2023; 13 Postlethwait (10.1016/j.biopha.2024.117503_bib12) 1998; 18 McGrath (10.1016/j.biopha.2024.117503_bib15) 2008; 13 Dorer (10.1016/j.biopha.2024.117503_bib8) 2016; 48 |
| References_xml | – volume: 6 year: 2011 ident: bib27 article-title: Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse publication-title: PLoS One contributor: fullname: Warner – volume: 20 start-page: 847 year: 2015 end-page: 848 ident: bib9 article-title: Ponatinib: accelerated disapproval publication-title: Oncologist contributor: fullname: Chabner – volume: 208 start-page: 299 year: 2023 end-page: 308 ident: bib18 article-title: Azoramide prevents MPP(+)-induced dopaminergic neuronal death via upregulating ER chaperone BiP expression publication-title: Free Radic. Biol. Med. contributor: fullname: Chong – volume: 246 start-page: 868 year: 2017 end-page: 880 ident: bib30 article-title: Heart function and hemodynamic analysis for zebrafish embryos publication-title: Dev. Dyn. contributor: fullname: Yacoub – volume: 21 start-page: 418 year: 2014 end-page: 422 ident: bib20 article-title: Zebrafish as a model system for the study of hemostasis and thrombosis publication-title: Curr. Opin. Hematol. contributor: fullname: Shavit – volume: 55 start-page: 1174 year: 2023 end-page: 1181 ident: bib50 article-title: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction publication-title: Exp. Mol. Med. contributor: fullname: Lee – volume: 16 year: 2024 ident: bib47 article-title: A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia publication-title: Pharmaceutics contributor: fullname: Di Paolo – volume: 115 start-page: 966 year: 2019 end-page: 977 ident: bib25 article-title: Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies publication-title: Cardiovasc Res. contributor: fullname: Lal – volume: 11 year: 2022 ident: bib28 article-title: Calcium channels in the heart: disease states and drugs publication-title: Cells contributor: fullname: Gururaja Rao – volume: 3 start-page: 2312 year: 2019 end-page: 2316 ident: bib32 article-title: Ponatinib treatment promotes arterial thrombosis and hyperactive platelets publication-title: Blood Adv. contributor: fullname: Schmaier – volume: 4 start-page: 2020 year: 2023 ident: bib39 article-title: Arachidonic acid metabolism in health and disease publication-title: MedComm contributor: fullname: Ma – volume: 365 start-page: 249 year: 2018 end-page: 261 ident: bib46 article-title: Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier publication-title: J. Pharmacol. Exp. Ther. contributor: fullname: Elmquist – volume: 16 start-page: 401 year: 2009 end-page: 412 ident: bib2 article-title: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance publication-title: Cancer Cell contributor: fullname: Clackson – volume: 10 start-page: 1028 year: 2011 end-page: 1035 ident: bib6 article-title: Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies publication-title: Mol. Cancer Ther. contributor: fullname: Rivera – volume: 17 start-page: 612 year: 2016 end-page: 621 ident: bib43 article-title: Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol. contributor: fullname: Investigators – volume: 64 start-page: 205 year: 2019 end-page: 209 ident: bib49 article-title: Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors publication-title: Chemotherapy contributor: fullname: Siragusa – volume: 11 start-page: 690 year: 2012 end-page: 699 ident: bib1 article-title: Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models publication-title: Mol. Cancer Ther. contributor: fullname: Rivera – volume: 37 start-page: 296 year: 2019 end-page: 302 ident: bib26 article-title: Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart publication-title: Hematol. Oncol. contributor: fullname: Breccia – volume: 906 start-page: 307 year: 2017 end-page: 324 ident: bib36 article-title: Role of P2Y(12) receptor in thrombosis publication-title: Adv. Exp. Med Biol. contributor: fullname: Ding – volume: 157 start-page: 483 year: 2012 end-page: 492 ident: bib5 article-title: Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation publication-title: Br. J. Haematol. contributor: fullname: Scholl – volume: 2 start-page: a006684 year: 2012 ident: bib29 article-title: Vascular development in the zebrafish publication-title: Cold Spring Harb. Perspect. Med. contributor: fullname: Weinstein – volume: 4 start-page: 530 year: 2020 end-page: 538 ident: bib33 article-title: Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia publication-title: Blood Adv. contributor: fullname: Pinilla-Ibarz – volume: 74 start-page: 793 year: 2014 end-page: 806 ident: bib10 article-title: Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia publication-title: Drugs contributor: fullname: Hoy – volume: 13 start-page: 394 year: 2008 end-page: 401 ident: bib15 article-title: Zebrafish: a predictive model for assessing drug-induced toxicity publication-title: Drug Discov. Today contributor: fullname: Li – volume: 82 start-page: 70 year: 2007 end-page: 80 ident: bib11 article-title: Zebrafish: An emerging model system for human disease and drug discovery publication-title: Clin. Pharmacol. Ther. contributor: fullname: Dicker – volume: 293 start-page: H3636 year: 2007 end-page: H3642 ident: bib38 article-title: Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction publication-title: Am. J. Physiol. Heart Circ. Physiol. contributor: fullname: Granger – volume: 12 start-page: 103 year: 2022 ident: bib16 article-title: Neuropathy-associated Fars2 deficiency affects neuronal development and potentiates neuronal apoptosis by impairing mitochondrial function publication-title: Cell Biosci. contributor: fullname: Chen – volume: 72 start-page: 619 year: 2011 end-page: 633 ident: bib35 article-title: Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy publication-title: Br. J. Clin. Pharmacol. contributor: fullname: Whatling – volume: 18 year: 2023 ident: bib41 article-title: Preventive effect and mechanism of Tibetan tea extract on thrombosis in arachidonic acid-induced zebrafish determined via RNA-seq transcriptome profiles publication-title: PLoS One contributor: fullname: Zhu – volume: 9 start-page: 31958 year: 2018 end-page: 31970 ident: bib19 article-title: Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway publication-title: Oncotarget contributor: fullname: Ge – volume: 376 start-page: 917 year: 2017 end-page: 927 ident: bib44 article-title: I. Investigators, long-term outcomes of imatinib treatment for chronic myeloid leukemia publication-title: N. Engl. J. Med. contributor: fullname: Druker – volume: 42 start-page: 282 year: 2014 end-page: 293 ident: bib3 article-title: Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA publication-title: Exp. Hematol. contributor: fullname: Valent – volume: 12 year: 2016 ident: bib51 article-title: Glycine and folate ameliorate models of congenital sideroblastic anemia publication-title: PLoS Genet contributor: fullname: McMaster – volume: 13 start-page: 335 year: 2016 end-page: 344 ident: bib21 article-title: A Zebrafish thrombosis model for assessing antithrombotic drugs publication-title: Zebrafish contributor: fullname: Li – volume: 11 year: 2021 ident: bib48 article-title: Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase publication-title: Front. Oncol. contributor: fullname: Breccia – volume: 181 start-page: 600 year: 2017 end-page: 608 ident: bib23 article-title: In vivo cardiovascular toxicity induced by acetochlor in zebrafish larvae publication-title: Chemosphere contributor: fullname: Zhu – volume: 135 start-page: 155 year: 2015 end-page: 160 ident: bib7 article-title: The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear publication-title: Thromb. Res contributor: fullname: McCarty – volume: 147 year: 2006 ident: bib37 article-title: Antiplatelet drugs publication-title: Br. J. Pharmacol. contributor: fullname: Patrono – volume: 48 start-page: 84 year: 2016 end-page: 91 ident: bib8 article-title: Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients publication-title: Leuk. Res. contributor: fullname: Haluska – volume: 16 start-page: 46 year: 2016 end-page: 53 ident: bib22 article-title: FGF2 prevents sunitinib-induced cardiotoxicity in zebrafish and cardiomyoblast H9c2 cells publication-title: Cardiovasc. Toxicol. contributor: fullname: Lee – volume: 18 start-page: 345 year: 1998 end-page: 349 ident: bib12 article-title: Vertebrate genome evolution and the zebrafish gene map publication-title: Nat. Genet. contributor: fullname: Talbot – volume: 352 start-page: 181 year: 2007 end-page: 187 ident: bib40 article-title: The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes publication-title: Biochem. Biophys. Res. Commun. contributor: fullname: Herschman – volume: 29 start-page: 2181 year: 2013 end-page: 2190 ident: bib4 article-title: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1 publication-title: Oncol. Rep. contributor: fullname: Hao – volume: 25 start-page: 904 year: 2003 end-page: 912 ident: bib13 article-title: Zebrafish: a new model on the pharmaceutical catwalk publication-title: Bioessays contributor: fullname: Langheinrich – volume: 29 start-page: 12970 year: 2009 end-page: 12981 ident: bib42 article-title: Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli publication-title: J. Neurosci. contributor: fullname: Sawchenko – volume: 12 year: 2024 ident: bib31 article-title: Zebrafish as a model for cardiovascular and metabolic disease: the future of precision medicine publication-title: Biomedicines contributor: fullname: Nakka – volume: 889 year: 2020 ident: bib24 article-title: Ponatinib-induced ischemic stroke in larval zebrafish for drug screening publication-title: Eur. J. Pharmacol. contributor: fullname: Li – volume: 14 start-page: 721 year: 2015 end-page: 731 ident: bib14 article-title: Zebrafish as tools for drug discovery publication-title: Nat. Rev. Drug Discov. contributor: fullname: Peterson – volume: 18 year: 2023 ident: bib34 article-title: Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors publication-title: PLoS One contributor: fullname: Jaffe – volume: 7 start-page: 2013 year: 2014 end-page: 2019 ident: bib45 article-title: The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells publication-title: Onco Targets Ther. contributor: fullname: Gao – volume: 13 start-page: 121 year: 2023 ident: bib17 article-title: Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma publication-title: Cell Biosci. contributor: fullname: Poliseno – volume: 16 start-page: 46 issue: 1 year: 2016 ident: 10.1016/j.biopha.2024.117503_bib22 article-title: FGF2 prevents sunitinib-induced cardiotoxicity in zebrafish and cardiomyoblast H9c2 cells publication-title: Cardiovasc. Toxicol. doi: 10.1007/s12012-015-9315-1 contributor: fullname: Cui – volume: 12 issue: 3 year: 2024 ident: 10.1016/j.biopha.2024.117503_bib31 article-title: Zebrafish as a model for cardiovascular and metabolic disease: the future of precision medicine publication-title: Biomedicines doi: 10.3390/biomedicines12030693 contributor: fullname: Angom – volume: 37 start-page: 296 issue: 3 year: 2019 ident: 10.1016/j.biopha.2024.117503_bib26 article-title: Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart publication-title: Hematol. Oncol. doi: 10.1002/hon.2606 contributor: fullname: Caocci – volume: 74 start-page: 793 issue: 7 year: 2014 ident: 10.1016/j.biopha.2024.117503_bib10 article-title: Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia publication-title: Drugs doi: 10.1007/s40265-014-0216-6 contributor: fullname: Hoy – volume: 147 issue: Suppl 1(Suppl 1 year: 2006 ident: 10.1016/j.biopha.2024.117503_bib37 article-title: Antiplatelet drugs publication-title: Br. J. Pharmacol. contributor: fullname: Born – volume: 82 start-page: 70 issue: 1 year: 2007 ident: 10.1016/j.biopha.2024.117503_bib11 article-title: Zebrafish: An emerging model system for human disease and drug discovery publication-title: Clin. Pharmacol. Ther. doi: 10.1038/sj.clpt.6100223 contributor: fullname: Kari – volume: 14 start-page: 721 issue: 10 year: 2015 ident: 10.1016/j.biopha.2024.117503_bib14 article-title: Zebrafish as tools for drug discovery publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd4627 contributor: fullname: MacRae – volume: 7 start-page: 2013 year: 2014 ident: 10.1016/j.biopha.2024.117503_bib45 article-title: The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells publication-title: Onco Targets Ther. contributor: fullname: Zhang – volume: 11 start-page: 690 issue: 3 year: 2012 ident: 10.1016/j.biopha.2024.117503_bib1 article-title: Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-11-0450 contributor: fullname: Gozgit – volume: 2 start-page: a006684 issue: 5 year: 2012 ident: 10.1016/j.biopha.2024.117503_bib29 article-title: Vascular development in the zebrafish publication-title: Cold Spring Harb. Perspect. Med. doi: 10.1101/cshperspect.a006684 contributor: fullname: Gore – volume: 11 year: 2021 ident: 10.1016/j.biopha.2024.117503_bib48 article-title: Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase publication-title: Front. Oncol. doi: 10.3389/fonc.2021.642005 contributor: fullname: Castagnetti – volume: 48 start-page: 84 year: 2016 ident: 10.1016/j.biopha.2024.117503_bib8 article-title: Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients publication-title: Leuk. Res. doi: 10.1016/j.leukres.2016.07.007 contributor: fullname: Dorer – volume: 365 start-page: 249 issue: 2 year: 2018 ident: 10.1016/j.biopha.2024.117503_bib46 article-title: Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.117.246116 contributor: fullname: Laramy – volume: 376 start-page: 917 issue: 10 year: 2017 ident: 10.1016/j.biopha.2024.117503_bib44 article-title: I. Investigators, long-term outcomes of imatinib treatment for chronic myeloid leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1609324 contributor: fullname: Hochhaus – volume: 18 start-page: 345 issue: 4 year: 1998 ident: 10.1016/j.biopha.2024.117503_bib12 article-title: Vertebrate genome evolution and the zebrafish gene map publication-title: Nat. Genet. doi: 10.1038/ng0498-345 contributor: fullname: Postlethwait – volume: 889 year: 2020 ident: 10.1016/j.biopha.2024.117503_bib24 article-title: Ponatinib-induced ischemic stroke in larval zebrafish for drug screening publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2020.173292 contributor: fullname: Zhu – volume: 72 start-page: 619 issue: 4 year: 2011 ident: 10.1016/j.biopha.2024.117503_bib35 article-title: Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/j.1365-2125.2011.03943.x contributor: fullname: Warner – volume: 42 start-page: 282 issue: 4 year: 2014 ident: 10.1016/j.biopha.2024.117503_bib3 article-title: Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA publication-title: Exp. Hematol. doi: 10.1016/j.exphem.2013.12.007 contributor: fullname: Sadovnik – volume: 18 issue: 5 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib41 article-title: Preventive effect and mechanism of Tibetan tea extract on thrombosis in arachidonic acid-induced zebrafish determined via RNA-seq transcriptome profiles publication-title: PLoS One doi: 10.1371/journal.pone.0285216 contributor: fullname: Wang – volume: 12 issue: 1 year: 2016 ident: 10.1016/j.biopha.2024.117503_bib51 article-title: Glycine and folate ameliorate models of congenital sideroblastic anemia publication-title: PLoS Genet doi: 10.1371/journal.pgen.1005783 contributor: fullname: Fernandez-Murray – volume: 29 start-page: 2181 issue: 6 year: 2013 ident: 10.1016/j.biopha.2024.117503_bib4 article-title: Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1 publication-title: Oncol. Rep. doi: 10.3892/or.2013.2386 contributor: fullname: Ren – volume: 12 start-page: 103 issue: 1 year: 2022 ident: 10.1016/j.biopha.2024.117503_bib16 article-title: Neuropathy-associated Fars2 deficiency affects neuronal development and potentiates neuronal apoptosis by impairing mitochondrial function publication-title: Cell Biosci. doi: 10.1186/s13578-022-00838-y contributor: fullname: Chen – volume: 16 issue: 3 year: 2024 ident: 10.1016/j.biopha.2024.117503_bib47 article-title: A new algorithm integrating molecular response, toxicity, and plasma level measures for ponatinib dose choice in patients affected by chronic myeloid leukemia publication-title: Pharmaceutics doi: 10.3390/pharmaceutics16030383 contributor: fullname: Galimberti – volume: 3 start-page: 2312 issue: 15 year: 2019 ident: 10.1016/j.biopha.2024.117503_bib32 article-title: Ponatinib treatment promotes arterial thrombosis and hyperactive platelets publication-title: Blood Adv. doi: 10.1182/bloodadvances.2019000034 contributor: fullname: Merkulova – volume: 64 start-page: 205 issue: 4 year: 2019 ident: 10.1016/j.biopha.2024.117503_bib49 article-title: Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors publication-title: Chemotherapy doi: 10.1159/000504664 contributor: fullname: Santoro – volume: 135 start-page: 155 issue: 1 year: 2015 ident: 10.1016/j.biopha.2024.117503_bib7 article-title: The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear publication-title: Thromb. Res doi: 10.1016/j.thromres.2014.11.009 contributor: fullname: Loren – volume: 9 start-page: 31958 issue: 62 year: 2018 ident: 10.1016/j.biopha.2024.117503_bib19 article-title: Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway publication-title: Oncotarget doi: 10.18632/oncotarget.24110 contributor: fullname: Ai – volume: 293 start-page: H3636 issue: 6 year: 2007 ident: 10.1016/j.biopha.2024.117503_bib38 article-title: Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction publication-title: Am. J. Physiol. Heart Circ. Physiol. doi: 10.1152/ajpheart.01105.2006 contributor: fullname: Tailor – volume: 352 start-page: 181 issue: 1 year: 2007 ident: 10.1016/j.biopha.2024.117503_bib40 article-title: The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2006.11.007 contributor: fullname: Ishikawa – volume: 13 start-page: 121 issue: 1 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib17 article-title: Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma publication-title: Cell Biosci. doi: 10.1186/s13578-023-01064-w contributor: fullname: De Paolo – volume: 208 start-page: 299 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib18 article-title: Azoramide prevents MPP(+)-induced dopaminergic neuronal death via upregulating ER chaperone BiP expression publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2023.08.021 contributor: fullname: Ai – volume: 55 start-page: 1174 issue: 6 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib50 article-title: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction publication-title: Exp. Mol. Med. doi: 10.1038/s12276-023-01002-3 contributor: fullname: Kim – volume: 13 start-page: 394 issue: 9-10 year: 2008 ident: 10.1016/j.biopha.2024.117503_bib15 article-title: Zebrafish: a predictive model for assessing drug-induced toxicity publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2008.03.002 contributor: fullname: McGrath – volume: 181 start-page: 600 year: 2017 ident: 10.1016/j.biopha.2024.117503_bib23 article-title: In vivo cardiovascular toxicity induced by acetochlor in zebrafish larvae publication-title: Chemosphere doi: 10.1016/j.chemosphere.2017.04.090 contributor: fullname: Liu – volume: 906 start-page: 307 year: 2017 ident: 10.1016/j.biopha.2024.117503_bib36 article-title: Role of P2Y(12) receptor in thrombosis publication-title: Adv. Exp. Med Biol. doi: 10.1007/5584_2016_123 contributor: fullname: Zhang – volume: 29 start-page: 12970 issue: 41 year: 2009 ident: 10.1016/j.biopha.2024.117503_bib42 article-title: Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.2373-09.2009 contributor: fullname: Garcia-Bueno – volume: 21 start-page: 418 issue: 5 year: 2014 ident: 10.1016/j.biopha.2024.117503_bib20 article-title: Zebrafish as a model system for the study of hemostasis and thrombosis publication-title: Curr. Opin. Hematol. doi: 10.1097/MOH.0000000000000075 contributor: fullname: Weyand – volume: 18 issue: 11 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib34 article-title: Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors publication-title: PLoS One doi: 10.1371/journal.pone.0294438 contributor: fullname: Wang – volume: 4 start-page: 530 issue: 3 year: 2020 ident: 10.1016/j.biopha.2024.117503_bib33 article-title: Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia publication-title: Blood Adv. doi: 10.1182/bloodadvances.2019000268 contributor: fullname: Chan – volume: 17 start-page: 612 issue: 5 year: 2016 ident: 10.1016/j.biopha.2024.117503_bib43 article-title: Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)00080-2 contributor: fullname: Lipton – volume: 246 start-page: 868 issue: 11 year: 2017 ident: 10.1016/j.biopha.2024.117503_bib30 article-title: Heart function and hemodynamic analysis for zebrafish embryos publication-title: Dev. Dyn. doi: 10.1002/dvdy.24497 contributor: fullname: Yalcin – volume: 25 start-page: 904 issue: 9 year: 2003 ident: 10.1016/j.biopha.2024.117503_bib13 article-title: Zebrafish: a new model on the pharmaceutical catwalk publication-title: Bioessays doi: 10.1002/bies.10326 contributor: fullname: Langheinrich – volume: 10 start-page: 1028 issue: 6 year: 2011 ident: 10.1016/j.biopha.2024.117503_bib6 article-title: Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-10-1044 contributor: fullname: Gozgit – volume: 115 start-page: 966 issue: 5 year: 2019 ident: 10.1016/j.biopha.2024.117503_bib25 article-title: Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies publication-title: Cardiovasc Res. doi: 10.1093/cvr/cvz006 contributor: fullname: Singh – volume: 4 start-page: 2020 issue: 5 year: 2023 ident: 10.1016/j.biopha.2024.117503_bib39 article-title: Arachidonic acid metabolism in health and disease publication-title: MedComm doi: 10.1002/mco2.363 contributor: fullname: Zhang – volume: 157 start-page: 483 issue: 4 year: 2012 ident: 10.1016/j.biopha.2024.117503_bib5 article-title: Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2012.09085.x contributor: fullname: Zirm – volume: 16 start-page: 401 issue: 5 year: 2009 ident: 10.1016/j.biopha.2024.117503_bib2 article-title: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.09.028 contributor: fullname: O'Hare – volume: 13 start-page: 335 issue: 4 year: 2016 ident: 10.1016/j.biopha.2024.117503_bib21 article-title: A Zebrafish thrombosis model for assessing antithrombotic drugs publication-title: Zebrafish doi: 10.1089/zeb.2016.1263 contributor: fullname: Zhu – volume: 6 issue: 5 year: 2011 ident: 10.1016/j.biopha.2024.117503_bib27 article-title: Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse publication-title: PLoS One doi: 10.1371/journal.pone.0020062 contributor: fullname: Armstrong – volume: 11 issue: 6 year: 2022 ident: 10.1016/j.biopha.2024.117503_bib28 article-title: Calcium channels in the heart: disease states and drugs publication-title: Cells doi: 10.3390/cells11060943 contributor: fullname: Shah – volume: 20 start-page: 847 issue: 8 year: 2015 ident: 10.1016/j.biopha.2024.117503_bib9 article-title: Ponatinib: accelerated disapproval publication-title: Oncologist doi: 10.1634/theoncologist.2015-0253 contributor: fullname: Gainor |
| SSID | ssj0005638 |
| Score | 2.4531546 |
| Snippet | Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+... Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph... Background: Ponatinib (Iclusig) is an oral tyrosine kinase BCR-ABL inhibitor for treating patients with Philadelphia chromosome-positive acute lymphoblastic... |
| SourceID | doaj proquest crossref pubmed elsevier |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 117503 |
| SubjectTerms | Aspirin Cardiovascular toxicity COX-1 Ponatinib Thrombosis Zebrafish |
| Title | Aspirin reduces Ponatinib-induced cardiovascular toxic phenotypes and death in zebrafish |
| URI | https://dx.doi.org/10.1016/j.biopha.2024.117503 https://www.ncbi.nlm.nih.gov/pubmed/39357328 https://www.proquest.com/docview/3112527150 https://doaj.org/article/757bb0282c0e4489ae08f5ef1af75a4b |
| Volume | 180 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtDqWXkqSv7QsVSk4RtS1rJR-TNiGXlqVNIfQi9BhR52CXOAtJfn1mLHtDDiWXXnwQRh48I803mtE3jH2SDr1eLKUAB4WoTQrCNMEJ6UBX0pnoRwLTk5_6-5n5ekQ0OZtWX1QTlumB84_7rJX2ngKDUACGEg1OaZKCVLqklav9uPsWZg6m5uKO5djDGv2hFBJtdr40N1Z2-bYnKiYM-2vKWaq5YdbklEbu_nu-6V_Yc_RBx9vs2QQe-UEWeoc9gm6XPfk2pcd32d4qE1Ff7_PTu3tVwz7f46s7iurr5-zsgBLsbccviLkVBr6iQ_S2a73AGB1HIg_3ClX5ZX_VBk4FYT2d2g7cdZFHwo8cp7mh9HNqhz8v2K_jo9MvJ2LqsSACnf0IiIXUDcgAJiiHsZlLJbgSgjF-WeJGniQohYsYYU7hogOZKhWrkHxduVjX8iXb6voOXjOOEyI6lKQijBp144L01TKkZCoZGkgLJuafbP9mKg0715id26wUS0qxWSkLdkia2LxLRNjjAJqHnczDPmQeC6ZnPdoJU2SsgFO1D3z-46x2i0uO8iiug349WIkYVVUaofSCvcr2sBGSbjoT_9Gb_yH8W_aUBMpXH9-xrcuLNbxnj4e4_jCaOz5_qx-3x3IFQA |
| link.rule.ids | 315,782,786,866,2108,27935,27936 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aspirin+reduces+Ponatinib-induced+cardiovascular+toxic+phenotypes+and+death+in+zebrafish&rft.jtitle=Biomedicine+%26+pharmacotherapy&rft.au=Yu%2C+Ruiqi&rft.au=Ai%2C+Nana&rft.au=Huang%2C+Chen&rft.au=Wang%2C+Danni&rft.date=2024-11-01&rft.pub=Elsevier+Masson+SAS&rft.issn=0753-3322&rft.volume=180&rft_id=info:doi/10.1016%2Fj.biopha.2024.117503&rft.externalDocID=S0753332224013891 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0753-3322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0753-3322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0753-3322&client=summon |